glp-1 and gip dual agonist This review summarizes how GIP/GLP-1 receptor agonists act at the cellular level and their therapeutic applications in metabolic diseases like type 2 diabetes and obesity, highlighting advances in incretin-based Fair Allocation of GLP-1 and

Description

Oral semaglutide reduces systolic blood pressure (SBP), BW and blood glucose levels

however, anti-drug antibodies have not been shown to impact drug effects in diabetes

9-11 Weight: Weight loss is seen with GLP-1 RAs as opposed to weight gain with insulin therapy

Acknowledgements This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License ( which permits any non-commercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made

In addition, studies have shown that DDP-4 vaccines and inhibitory anti-DDP-4 antibody also have therapeutic potential due to their ability to improve glucose metabolism in mice